{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T02:12:41Z","timestamp":1779934361768,"version":"3.53.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"S1","license":[{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,7,1]]},"abstract":"<jats:p>Strabismus, deviation of the ocular alignment, can adversely affect quality of life and activities of daily living. Surgery was the prior standard of care for strabismus, but up to 40% of patients required additional surgeries. This need for more effective and less invasive treatment, along with the convergence of other events such as the development of electromyography, purification of botulinum toxin A, and the finding that injection of botulinum toxin type A could paralyze the hind limbs of chicks, led Dr. Alan Scott to investigate injection of his formulation for strabismus. The positive results of initial trials in monkeys segued to human trials with observations of alignment improvements and few adverse events. The success of botulinum toxin type A in the treatment of strabismus led to interest in its use to treat other skeletal muscles, particularly in blepharospasm, a type of focal dystonia involving eyelid spasms and involuntary eye closure that lacked an effective pharmacological treatment. Patient groups helped to increase awareness of this novel treatment, and results from clinical trials confirmed its effectiveness. Dr. Scott\u2019s formulation, then known as Oculinum, received its first Food and Drug Administration approvals in 1989 for strabismus and blepharospasm. Allergan acquired Oculinum in 1991, renaming it Botox. These initial uses led to its application in a myriad of other indications as outlined in other articles of this supplement.<\/jats:p>","DOI":"10.1097\/md.0000000000032374","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:01:22Z","timestamp":1690484482000},"page":"e32374","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":13,"title":["Treatment of strabismus and blepharospasm with Botox (onabotulinumtoxinA): Development, insights, and impact"],"prefix":"10.1097","volume":"102","author":[{"given":"Alan B.","family":"Scott","sequence":"first","affiliation":[{"name":"Strabismus Research Foundation, San Francisco, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanley","family":"Fahn","sequence":"additional","affiliation":[{"name":"Columbia University, New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell F.","family":"Brin","sequence":"additional","affiliation":[{"name":"Allergan\/AbbVie, Irvine, CA, USA"},{"name":"University of California, Irvine, CA, USA."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20240803","first-page":"Cd006499","article-title":"Botulinum toxin for the treatment of strabismus.","volume":"3","author":"Rowe","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"key":"R3-20240803","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1080\/09273972.2019.1604773","article-title":"Global and regional prevalence of strabismus: a comprehensive systematic review and meta-analysis.","volume":"27","author":"Hashemi","year":"2019","journal-title":"Strabismus"},{"key":"R4-20240803","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/aos.14112","article-title":"The Danish Rural Eye Study: prevalence of strabismus among 3785 Danish adults \u2013 a population-based cross-sectional study.","volume":"97","author":"Hultman","year":"2019","journal-title":"Acta Ophthalmol"},{"key":"R5-20240803","doi-asserted-by":"crossref","first-page":"45","DOI":"10.3389\/fneur.2016.00045","article-title":"Blepharospasm: update on epidemiology, clinical aspects, and pathophysiology.","volume":"7","author":"Valls-Sole","year":"2016","journal-title":"Front Neurol"},{"key":"R6-20240803","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/mds.26934","article-title":"Blepharospasm 40 years later.","volume":"32","author":"Defazio","year":"2017","journal-title":"Mov Disord"},{"key":"R7-20240803","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1002\/mds.1275","article-title":"Epidemiology of primary blepharospasm.","volume":"17","author":"Defazio","year":"2002","journal-title":"Mov Disord"},{"key":"R8-20240803","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1136\/jnnp.64.1.25","article-title":"Possible risk factors for primary adult onset dystonia: a case-control investigation by the Italian Movement Disorders Study Group.","volume":"64","author":"Defazio","year":"1998","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"R9-20240803","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/mds.23011","article-title":"The phenomenology of the geste antagoniste in primary blepharospasm and cervical dystonia.","volume":"25","author":"Martino","year":"2010","journal-title":"Mov Disord"},{"key":"R10-20240803","first-page":"453","article-title":"Essential blepharospasm.","volume":"54","author":"Henderson","year":"1956","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R11-20240803","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1080\/01658100701247646","article-title":"Shedding light on blepharospasm: a patient\u2013researcher partnership approach to assessment of photophobia and impact on activities of daily living.","volume":"31","author":"Judd","year":"2007","journal-title":"Neuro-Ophthalmol"},{"key":"R12-20240803","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1212\/01.wnl.0000311389.26145.95","article-title":"Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the therapeutics and technology assessment subcommittee of the American academy of neurology.","volume":"70","author":"Simpson","year":"2008","journal-title":"Neurology"},{"key":"R13-20240803","first-page":"367","article-title":"Management of blepharospasm.","volume":"83","author":"Waller","year":"1985","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R14-20240803","first-page":"24","article-title":"Treatment of blepharospasm with medication, surgery and type A botulinum toxin.","volume":"22","author":"Arthurs","year":"1987","journal-title":"Can J Ophthalmol"},{"key":"R15-20240803","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1212\/WNL.34.2.215","article-title":"Cranial dystonia: double-blind crossover study of anticholinergics.","volume":"34","author":"Nutt","year":"1984","journal-title":"Neurology"},{"key":"R16-20240803","first-page":"219","article-title":"Long term usefulness of baclofen in the treatment of essential blepharospasm.","volume":"4","author":"Fahn","year":"1985","journal-title":"Adv Ophthal Plastic Reconst Surg"},{"key":"R17-20240803","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1002\/ana.410130406","article-title":"Blepharospasm and orofacial-cervical dystonia: clinical and pharmacological findings in 100 patients.","volume":"13","author":"Jankovic","year":"1983","journal-title":"Ann Neurol"},{"key":"R18-20240803","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1001\/archopht.1981.03930011056015","article-title":"Blepharospasm surgery. An anatomical approach.","volume":"99","author":"Gillum","year":"1981","journal-title":"Arch Ophthalmol"},{"key":"R19-20240803","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00415-011-6380-7","article-title":"History of the \u201cgeste antagoniste\u201d sign in cervical dystonia.","volume":"259","author":"Poisson","year":"2012","journal-title":"J Neurol"},{"key":"R20-20240803","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s00702-007-0728-2","article-title":"From poison to remedy: the chequered history of botulinum toxin.","volume":"115","author":"Erbguth","year":"2008","journal-title":"J Neural Transm (Vienna)"},{"key":"R23-20240803","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1128\/mr.56.1.80-99.1992","article-title":"Properties and use of botulinum toxin and other microbial neurotoxins in medicine.","volume":"56","author":"Schantz","year":"1992","journal-title":"Microbiol Rev"},{"key":"R24-20240803","first-page":"734","article-title":"Botulinum toxin injection of eye muscles to correct strabismus.","volume":"79","author":"Scott","year":"1981","journal-title":"Trans Am Ophthalmol Soc"},{"key":"R25-20240803","first-page":"924","article-title":"Pharmacologic weakening of extraocular muscles.","volume":"12","author":"Scott","year":"1973","journal-title":"Invest Ophthalmol"},{"key":"R26-20240803","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/S0161-6420(80)35127-0","article-title":"Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.","volume":"87","author":"Scott","year":"1980","journal-title":"Ophthalmology"},{"issue":"4 Suppl 1","key":"R27-20240803","first-page":"271","article-title":"Double-blind controlled study of botulinum toxin for blepharospasm.","volume":"35","author":"Fahn","year":"1985","journal-title":"Neurology"},{"key":"R28-20240803","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1002\/mds.870020402","article-title":"Localized injections of botulinum toxin for the treatment of focal dystonia and hemifacial spasm.","volume":"2","author":"Brin","year":"1987","journal-title":"Mov Disord"},{"key":"R29-20240803","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1001\/archopht.1985.01050030043017","article-title":"Botulinum A toxin injection as a treatment for blepharospasm.","volume":"103","author":"Scott","year":"1985","journal-title":"Arch Ophthalmol"},{"key":"R31-20240803","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3109\/09273972.2014.907815","article-title":"Sustained improvement of reading symptoms following botulinum toxin A injection for convergence insufficiency.","volume":"22","author":"Saunte","year":"2014","journal-title":"Strabismus"},{"key":"R32-20240803","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.toxicon.2012.12.004","article-title":"Evidence-based review and assessment of botulinum neurotoxin for the treatment of movement disorders.","volume":"67","author":"Hallett","year":"2013","journal-title":"Toxicon"},{"key":"R33-20240803","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1212\/WNL.37.4.616","article-title":"Botulinum A toxin for cranial-cervical dystonia: a double-blind, placebo-controlled study.","volume":"37","author":"Jankovic","year":"1987","journal-title":"Neurology"},{"key":"R34-20240803","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.survophthal.2006.10.003","article-title":"Botulinum toxin in ophthalmology.","volume":"52","author":"Dutton","year":"2007","journal-title":"Surv Ophthalmol"},{"key":"R35-20240803","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1007\/PL00007849","article-title":"Comparison of preseptal and pretarsal injections of botulinum toxin in the treatment of blepharospasm and hemifacial spasm.","volume":"249","author":"\u00c7akmur","year":"2002","journal-title":"J Neurol"},{"key":"R36-20240803","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1007\/s10072-017-3107-2","article-title":"A comparative crossover study on the treatment of hemifacial spasm and blepharospasm: preseptal and pretarsal botulinum toxin injection techniques.","volume":"38","author":"Lolekha","year":"2017","journal-title":"Neurol Sci"},{"key":"R37-20240803","first-page":"227","article-title":"Botulinum toxin type A products are not interchangeable: a review of the evidence.","volume":"8","author":"Brin","year":"2014","journal-title":"Biologics"},{"key":"R38-20240803","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1017\/cjn.2016.262","article-title":"Real-world, long-term quality of life following therapeutic onabotulinumtoxinA treatment.","volume":"43","author":"Jog","year":"2016","journal-title":"Can J Neurol Sci"},{"key":"R39-20240803","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1002\/mds.10252","article-title":"Long-term efficacy of botulinum toxin A in treatment of various movement disorders over a 10-year period.","volume":"17","author":"Hsiung","year":"2002","journal-title":"Mov Disord"},{"key":"R40-20240803","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1038\/eye.2009.192","article-title":"Long-term efficacy of botulinum toxin A for treatment of blepharospasm, hemifacial spasm, and spastic entropion: a multicentre study using two drug-dose escalation indexes.","volume":"24","author":"Cillino","year":"2010","journal-title":"Eye (Lond)"},{"key":"R41-20240803","doi-asserted-by":"crossref","first-page":"1332","DOI":"10.1212\/WNL.40.9.1332","article-title":"Assessment: the clinical usefulness of botulinum toxin-A in treating neurologic disorders. Report of the Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology.","volume":"40","year":"1990","journal-title":"Neurology"},{"key":"R42-20240803","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1001\/archneur.1991.00530240100030","article-title":"Institutes of Health Consensus Development Conference Statement, November 12-14, 1990.","volume":"48","year":"1991","journal-title":"Arch Neurol"},{"key":"R43-20240803","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1212\/WNL.44.12.2401","article-title":"Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology, Training guidelines for the use of botulinum toxin for the treatment of neurologic disorders.","volume":"44","year":"1994","journal-title":"Neurology"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032374","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,4]],"date-time":"2024-08-04T01:56:36Z","timestamp":1722736596000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000032374"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,1]]},"references-count":39,"journal-issue":{"issue":"S1","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000032374","relation":{},"ISSN":["0025-7974"],"issn-type":[{"value":"0025-7974","type":"print"}],"subject":[],"published":{"date-parts":[[2023,7,1]]}}}